SCTX · Scribe Therapeutics, Inc. · Analyst Estimates
$33.00
+0.86 (+2.68%)
At close · Sep 18
Going-concern doubt
— cleared Sep 2, 2026
The latest filing states the doubt was alleviated.
“Substantial doubt about our ability to continue as a going concern existed as of June 30, 2026 and was alleviated as a result of the completion of our initial public offering and concurrent private placement, which resulted in aggregate net proceeds of approximately $140.7 million.”View the 10-Q filed Sep 2, 2026
Market Cap
$578.48M
Shares
18.93M
Analyst Estimates
Compare analyst forecasts for Scribe Therapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-09-18 07:05 UTC · Publication dates shown per estimate · 16 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 30 days ago | Average, 60 days ago | Average, 7 days ago | Average, 90 days ago | Estimates lowered, last 30 days | Estimates lowered, last 7 days | Estimates raised, last 30 days | Estimates raised, last 7 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-6.63
|
-5.59
|
-4.55
|
— |
0.0
|
0.0
|
-5.925
|
0.0
|
— | — | — | — |
|
EPS
analysts
Publication date not stated |
— | — | — |
2
|
— | — | — | — |
0
|
0
|
0
|
2
|
|
Revenue
USD
Publication date not stated |
4000000
|
11568200
|
26090000
|
— | — | — | — | — | — | — | — | — |
|
Revenue
analysts
Publication date not stated |
— | — | — |
5
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 30 days ago | Average, 60 days ago | Average, 7 days ago | Average, 90 days ago | Estimates lowered, last 30 days | Estimates lowered, last 7 days | Estimates raised, last 30 days | Estimates raised, last 7 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-4.47
|
-3.61667
|
-3.11
|
— |
0.0
|
0.0
|
-3.45
|
0.0
|
— | — | — | — |
|
EPS
analysts
Publication date not stated |
— | — | — |
3
|
— | — | — | — |
0
|
2
|
0
|
1
|
|
Revenue
USD
Publication date not stated |
0
|
6730000
|
10950000
|
— | — | — | — | — | — | — | — | — |
|
Revenue
analysts
Publication date not stated |
— | — | — |
5
|
— | — | — | — | — | — | — | — |
Q ending 2026-09-30
| Metric | Low | Average | High | Analyst count | Average, 30 days ago | Average, 60 days ago | Average, 7 days ago | Average, 90 days ago | Estimates lowered, last 30 days | Estimates lowered, last 7 days | Estimates raised, last 30 days | Estimates raised, last 7 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-1.46
|
-1.03
|
-0.75
|
— |
0.0
|
0.0
|
-1.05333
|
0.0
|
— | — | — | — |
|
EPS
analysts
Publication date not stated |
— | — | — |
3
|
— | — | — | — |
0
|
0
|
0
|
1
|
|
Revenue
USD
Publication date not stated |
0
|
3720000
|
11000000
|
— | — | — | — | — | — | — | — | — |
|
Revenue
analysts
Publication date not stated |
— | — | — |
5
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 30 days ago | Average, 60 days ago | Average, 7 days ago | Average, 90 days ago | Estimates lowered, last 30 days | Estimates lowered, last 7 days | Estimates raised, last 30 days | Estimates raised, last 7 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-1.55
|
-1.06
|
-0.51
|
— |
0.0
|
0.0
|
-0.98333
|
0.0
|
— | — | — | — |
|
EPS
analysts
Publication date not stated |
— | — | — |
3
|
— | — | — | — |
0
|
1
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
0
|
3707800
|
10939000
|
— | — | — | — | — | — | — | — | — |
|
Revenue
analysts
Publication date not stated |
— | — | — |
5
|
— | — | — | — | — | — | — | — |